Maryam Ghaffari1, Gholamreza Dehghan2, Behzad Baradaran3, Amir Zarebkohan4, Behzad Mansoori3, Jafar Soleymani5, Jafar Ezzati Nazhad Dolatabadi6, Michael R Hamblin7. 1. Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. 2. Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran. 3. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 4. Department of Medical Nanotechnology, Faculty of Advanced Medical Science, Tabriz University of Medical Science, Tabriz, Iran. 5. Pharmaceutical Analysis Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 6. Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: ezzatij@tbzmed.ac.ir. 7. Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Dermatology, Harvard Medical School, Boston, MA 02115, USA; Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein 2028, South Africa. Electronic address: hamblin@helix.mgh.harvard.edu.
Abstract
Co-delivery of therapeutic agents and small interfering RNA (siRNA) can be achieved by a suitable nanovehicle. In this work, the solubility and bioavailability of curcumin (Cur) were enhanced by entrapment in a polyamidoamine (PAMAM) dendrimer, and a polyplex was formed by grafting Bcl-2 siRNA onto the surface amine groups to produce PAMAM-Cur/Bcl-2 siRNA nanoparticles (NPs). The synthesized polyplex NPs had a particle size of ∼180 nm, and high Cur loading content of ∼82 wt%. Moreover, the PAMAM-Cur/Bcl-2 siRNA NPs showed more effective cellular uptake, and higher inhibition of tumor cell proliferation compared to PAMAM-Cur nanoformulation and free Cur, due to the combined effect of co-delivery of Cur and Bcl-2 siRNA. The newly described PAMAM-Cur/Bcl-2 siRNA polyplex NPs could be a promising co-delivery nanovehicle.
Co-delivery of therapn>eutic agents ann>an class="Chemical">d small interfering RNA (siRNA) can be achieved by a suitable nanovehicle. In this work, the solubility and bioavailability of curcumin (Cur) were enhanced by entrapment in a polyamidoamine (PAMAM) dendrimer, and a polyplex was formed by grafting Bcl-2 siRNA onto the surface amine groups to produce PAMAM-Cur/Bcl-2 siRNA nanoparticles (NPs). The synthesized polyplex NPs had a particle size of ∼180 nm, and high Cur loading content of ∼82 wt%. Moreover, the PAMAM-Cur/Bcl-2 siRNA NPs showed more effective cellular uptake, and higher inhibition of tumor cell proliferation compared to PAMAM-Cur nanoformulation and free Cur, due to the combined effect of co-delivery of Cur andBcl-2 siRNA. The newly describedPAMAM-Cur/Bcl-2 siRNA polyplex NPs could be a promising co-delivery nanovehicle.
Authors: M Danaei; M Dehghankhold; S Ataei; F Hasanzadeh Davarani; R Javanmard; A Dokhani; S Khorasani; M R Mozafari Journal: Pharmaceutics Date: 2018-05-18 Impact factor: 6.321
Authors: Thomas Efferth; Mohamed E M Saeed; Elhaj Mirghani; Awadh Alim; Zahir Yassin; Elfatih Saeed; Hassan E Khalid; Salah Daak Journal: Oncotarget Date: 2017-07-25
Authors: Krzysztof Sztandera; Michał Gorzkiewicz; Ana Sofia Dias Martins; Lorenzo Pallante; Eric Adriano Zizzi; Marcello Miceli; Mateusz Ba Tal; Catarina Pinto Reis; Marco A Deriu; Barbara Klajnert-Maculewicz Journal: J Med Chem Date: 2021-09-21 Impact factor: 7.446
Authors: Sofía Mirón-Barroso; Joana S Correia; Adam E Frampton; Mark P Lythgoe; James Clark; Laura Tookman; Silvia Ottaviani; Leandro Castellano; Alexandra E Porter; Theoni K Georgiou; Jonathan Krell Journal: Noncoding RNA Date: 2022-08-02
Authors: Krzysztof Sztandera; Michał Gorzkiewicz; Mateusz Bątal; Valeria Arkhipova; Nadezhda Knauer; Javier Sánchez-Nieves; Fco Javier de la Mata; Rafael Gómez; Evgeny Apartsin; Barbara Klajnert-Maculewicz Journal: Int J Nanomedicine Date: 2022-03-15